S S Legha
About
In The Last Decade
S S Legha
25 papers receiving 927 citations
Peers
Comparison fields: 5 of 77
- Oncology 635
- Molecular Biology 388
- Immunology 308
- Ophthalmology 129
- Hematology 110
Countries citing papers authored by S S Legha
This map shows the geographic impact of S S Legha's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by S S Legha with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites S S Legha more than expected).
Fields of papers citing papers by S S Legha
This network shows the impact of papers produced by S S Legha. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by S S Legha. The network helps show where S S Legha may publish in the future.
Co-authorship network of co-authors of S S Legha
This figure shows the co-authorship network connecting the top 25 collaborators of S S Legha. A scholar is included among the top collaborators of S S Legha based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with S S Legha. S S Legha is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 2 | |
| 2 | 40 | |
| 3 | Active immunotherapy with ultraviolet B-irradiated autologous whole melanoma cells plus DETOX in patients with metastatic melanoma. | 23 |
| 4 | 221 | |
| 5 | 167 | |
| 6 | 15 | |
| 7 | The role of interferon alfa in the treatment of metastatic melanoma. | 42 |
| 8 | 62 | |
| 9 | Combination of chemotherapy with interleukin-2 and interferon-alfa for the treatment of advanced melanoma. | 40 |
| 10 | 21 | |
| 11 | 60 | |
| 12 | Phase II studies of homoharringtonine in patients with advanced malignant melanoma; sarcoma; and head and neck, breast, and colorectal carcinomas. | 19 |
| 13 | 11 | |
| 14 | 19 | |
| 15 | 85 | |
| 16 | 4 | |
| 17 | High-dose AMSA and bone marrow rescue in patients with solid tumors. | 9 |
| 18 | 1 | |
| 19 | 21 | |
| 20 | Clinical studies with rubidazone. | 10 |
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.